Nordea Investment Management AB raised its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 11.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 129,046 shares of the company’s stock after acquiring an additional 13,439 shares during the period. Nordea Investment Management AB owned 0.28% of Amphastar Pharmaceuticals worth $2,306,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Alps Advisors Inc. raised its holdings in Amphastar Pharmaceuticals by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 39,250 shares of the company’s stock valued at $701,000 after acquiring an additional 101 shares during the last quarter. Municipal Employees Retirement System of Michigan grew its stake in shares of Amphastar Pharmaceuticals by 2.8% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 8,430 shares of the company’s stock valued at $151,000 after buying an additional 230 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Amphastar Pharmaceuticals by 1.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 28,701 shares of the company’s stock valued at $512,000 after buying an additional 312 shares during the period. Victory Capital Management Inc. grew its stake in shares of Amphastar Pharmaceuticals by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 5,611 shares of the company’s stock valued at $100,000 after buying an additional 842 shares during the period. Finally, Thrivent Financial For Lutherans grew its stake in shares of Amphastar Pharmaceuticals by 7.2% during the 2nd quarter. Thrivent Financial For Lutherans now owns 21,610 shares of the company’s stock valued at $386,000 after buying an additional 1,460 shares during the period. Institutional investors own 44.14% of the company’s stock.
In other Amphastar Pharmaceuticals news, Director Stephen B. Shohet sold 7,862 shares of the business’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $19.25, for a total value of $151,343.50. Following the transaction, the director now owns 31,978 shares in the company, valued at approximately $615,576.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO William J. Peters sold 3,026 shares of the business’s stock in a transaction on Friday, October 13th. The stock was sold at an average price of $18.56, for a total transaction of $56,162.56. The disclosure for this sale can be found here. Insiders sold a total of 186,666 shares of company stock worth $3,451,064 in the last quarter. 11.10% of the stock is currently owned by company insiders.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, November 8th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.05. Amphastar Pharmaceuticals had a net margin of 0.12% and a return on equity of 2.30%. The firm had revenue of $57.90 million for the quarter, compared to analyst estimates of $57.23 million. During the same quarter in the previous year, the business posted $0.14 EPS. The firm’s revenue was down 9.8% compared to the same quarter last year. analysts anticipate that Amphastar Pharmaceuticals, Inc. will post -0.03 earnings per share for the current year.
Amphastar Pharmaceuticals declared that its Board of Directors has approved a share repurchase program on Wednesday, August 9th that permits the company to repurchase $20.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 2.8% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.
Several analysts have recently issued reports on AMPH shares. Piper Jaffray Companies set a $19.00 price objective on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. BidaskClub cut shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Jefferies Group reissued a “buy” rating and set a $19.00 price objective (down from $20.00) on shares of Amphastar Pharmaceuticals in a research note on Friday, August 11th. ValuEngine cut shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Finally, Needham & Company LLC upped their price target on shares of Amphastar Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, September 27th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $20.86.
WARNING: This piece was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/12/06/nordea-investment-management-ab-has-2-31-million-holdings-in-amphastar-pharmaceuticals-inc-amph.html.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.